



Integra LifeSciences Names Gabrielle Wolfson Chief Information Officer

PLAINSBORO, N.J., Aug 18, 2008 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today the appointment of Gabrielle Wolfson as Chief Information Officer, effective immediately.

Ms. Wolfson brings to Integra over 20 years of experience in Information Technology. As CIO, Ms. Wolfson will be responsible for Integra's global IT strategy and operations.

"We are delighted that Gabrielle is joining the Integra team," said Gerard Carlozzi, Integra's Executive Vice President and Chief Operating Officer. "Our IT systems and operations are a critical business component, and Gabrielle brings a wealth of experience that will enhance our use of information technology."

Ms. Wolfson was most recently at Par Pharmaceuticals (Par), where she was Vice President and Chief Information Officer. During her tenure at Par, Ms. Wolfson transformed the IT organization into a strategic business partner and led the implementation of technology solutions that streamlined operations and enabled the company to reach its business objectives. Prior to her tenure with Par, Ms Wolfson held senior IT management positions at PricewaterhouseCoopers LLP, Pernod Ricard Group, and Viacom/Showtime Networks. Inc.

"I am excited to join Integra, an organization with a proven record for success and a continued dedication to improving the quality of life for patients," said Ms. Wolfson. "The IT organization will focus on contributing to Integra's future success, through the delivery of technology solutions that will support the company's global business strategy."

Ms. Wolfson received her undergraduate degree in Mathematics from Queens College.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. The company's products are used to treat millions of patients every year, primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery. Integra's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. www.Integra-LS.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. The economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in section IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2007 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART-G

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation

John B. Henneman, III, Executive Vice
President, Finance and Administration,
and Chief Financial Officer
(609) 936-2481

jhenneman@Integra-LS.com

Gianna Sabella, Public Relations Manager
(609) 936-2389

gsabella@intergra-LS.com

(C) Copyright 2008 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX